Antirheumatic in SARS-CoV-2: benefit or risk?

Abstract

Not available

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2020-04-29
Info
Issue
Section
Letters to the Editor
Keywords:
SARS-CoV-2, anti-rheumatic, COVID-19, infection, immunology.
Statistics
  • Abstract views: 368

  • PDF: 182
  • HTML: 0
How to Cite
Ferrara, F. (2020). Antirheumatic in SARS-CoV-2: benefit or risk?. Italian Journal of Medicine, 14(2), 114-115. https://doi.org/10.4081/itjm.2020.1290

Most read articles by the same author(s)